Last reviewed · How we verify
Primary myelofibrosis — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Inrebic | FEDRATINIB HYDROCHLORIDE | Bristol-Myers Squibb | JAK2, FLT3 | 2019-01-01 | ||
| Inrebic | FEDRATINIB | Bristol-Myers Squibb | Cyclin-G-associated kinase | 2019-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Bristol-Myers Squibb · 2 drugs in Primary myelofibrosis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Primary myelofibrosis:
- Primary myelofibrosis treatment updates — RSS
- Primary myelofibrosis treatment updates — Atom
- Primary myelofibrosis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Primary myelofibrosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/primary-myelofibrosis. Accessed 2026-06-10.
Related
- Primary myelofibrosis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing